Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
ARCAGY/ GINECO GROUP
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07637851CT.gov Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07064018CT.gov Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | — | Recruiting | — | — | — |
NCT02470559CT.gov Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent | — | Withdrawn | — | — | — |
NCT00803569CT.gov Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | — | Completed | — | — | — |
NCT00569673CT.gov Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT00562640CT.gov Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | — | Completed | — | — | — |
NCT00432094CT.gov Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | — | Completed | — | — | — |
NCT00551122CT.gov Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors | — | Unknown | — | — | — |
NCT00091273CT.gov Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT00004157CT.gov Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | — | Completed | — | — | — |
Show 17 more trialsShow fewer
NCT00005956CT.gov Biological Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00005023CT.gov Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer | — | Completed | — | — | — |
NCT00003926CT.gov Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | — | Terminated | — | — | — |
NCT00003657CT.gov High-dose ICE With Amifostine | — | Completed | — | — | — |
NCT00003408CT.gov Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | — | Completed | — | — | — |
NCT00003852CT.gov Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | — | Terminated | — | — | — |
NCT00003269CT.gov Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
NCT00003425CT.gov Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | — | Completed | — | — | — |
NCT00003173CT.gov High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT00002977CT.gov Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission | — | Completed | — | — | — |
NCT00003064CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | — | Unknown | — | — | — |
NCT00003136CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT00003080CT.gov Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer | — | Completed | — | — | — |
NCT00003002CT.gov HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00019084CT.gov Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00002641CT.gov Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | — | Completed | — | — | — |
NCT00002515CT.gov Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | ARCAGY/ GINECO GROUP | P3 | BB · 64 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-ovarian-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →